BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, July 27, 2026
Home » breast cancer

Articles Tagged with ''breast cancer''

CAR T cell attacking cancer cells
Immuno-oncology

Series A financing at Tikva Allocell to advance TAVST-01

July 23, 2026
No Comments
Tikva Allocell Pte. Ltd. has closed an $8 million series A financing to support its development of engineered, allogeneic cell therapies for adult and pediatric patients with solid tumors.
Read More
Cancer

M-511-0965 blocks YAP-TEAD4 signaling in TNBC

July 22, 2026
No Comments
In breast cancer, dysregulated Hippo signaling results in activation of the YAP/TAZ-TEAD transcriptional complex, which induces a broad oncogenic transcriptional program. This gene expression network promotes tumor cell proliferation, survival, invasion and metastatic dissemination, while also contributing to resistance to anticancer therapies. Researchers from Harbin Medical University reported the preclinical characterization of M-511-0965, a YAP-TEAD4 inhibitor, in models of triple-negative breast cancer (TNBC).
Read More
Cancer tumor in breast illustration
Cancer

New PROTAC tackles ESR1-mutated breast cancer

July 20, 2026
No Comments
Researchers from Wuhan University and collaborators reported the synthesis and preclinical characterization of NCP07, a novel ERα PROTAC degrader designed to treat endocrine therapy-resistant tumors.
Read More
Revtorpyk

Celcuity’s Revtorpyk wins FDA nod in breast cancer

July 15, 2026
By Jennifer Boggs
No Comments
For the second time in two months, Celcuity Inc. failed to generate investor excitement despite disclosing positive news, this time following the U.S. FDA approval of Revtorpyk (gedatolisib) in a subset of breast cancer patients, marking the firm’s first foray into the commercial space and introducing a new treatment option for patients. Wall Street instead focused on an unanticipated launch delay, sending shares of Celcuity (NASDAQ:CELC) down 17.6% to close July 15 at $91.51.
Read More
Illustration of lymphocytes attacking cancer cell
Immuno-oncology

Coregen’s CRG-150 gains IND clearance for solid tumors

July 8, 2026
No Comments
Coregen Inc. has obtained IND clearance from the FDA for CRG-150, a novel adoptive cell therapy targeting SRC-3 (steroid receptor coactivator 3).
Read More
Illustration of tumor in breast
Cancer

Astex Pharmaceuticals and Genentech collaborate in breast cancer

July 7, 2026
No Comments
Astex Pharmaceuticals Ltd. has entered into an exclusive, worldwide research collaboration and license agreement with Genentech Inc., a member of the Roche Group, to identify small-molecule drug candidates with selective inhibitory activity as potential treatments for breast cancer.
Read More
Illustration of triple-negative breast cancer cells
Cancer

EVmiR-885-5p limits TNBC spread in preclinical models

June 22, 2026
No Comments
Researchers at Theramir Ltd. presented preclinical proof-of-concept data for a new extracellular vesicle (EV) platform engineered to deliver miR-885-5p (EVmiR885-5p), targeting leukocyte-specific protein-1 (LCP-1)-mediated cytoskeletal remodeling in triple-negative breast cancer (TNBC) models.
Read More
3D dollar sign

Ona raises $86.6M series B for ADCs to treat advanced cancers

June 4, 2026
By Nuala Moran
No Comments
Antibody-drug conjugate (ADC) specialist Ona Therapeutics SL has closed an oversubscribed series B at $86.6 million, as clinical development of the lead program ONA-255 in advanced treatment-resistant breast cancer gathers steam.
Read More
Dollar sign between hands

Mammogen raises $30M for blood-based breast cancer detection assay

June 3, 2026
By Shani Alexander
No Comments
Mammogen Inc. raised $30 million in equity financing in a series A round to support the clinical advancement and commercialization of its RNA-powered molecular diagnostics platform. The company’s lead product is Gentru-breast, a blood-based assay designed to detect molecular signatures associated with breast cancer from a simple blood draw.
Read More
Breast cancer cell

ASCO 2026: Celcuity’s positive phase III gets no love from investors

June 2, 2026
By Brian Orelli
No Comments
Minneapolis-based Celcuity Inc. was like the Rolling Stones at the 2026 American Society of Clinical Oncology annual meeting. The company reported positive phase III data for its pan-PI3K/mTORC1/2 inhibitor gedatolisib, but Celcuity (NASDAQ:CELC) couldn’t get any satisfaction from investors who sent shares down 25.7%, or $31.54, to $91.42 on June 2, 2026.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 79 80 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 24, 2026.
  • Cell nucleus architecture

    4D Nucleome opens new wave of gene regulation research, discovery

    BioWorld
    After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
  • Drug capsule spilling onto brain

    Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

    BioWorld Science
    Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
  • Business pipeline illustration

    Transcripta Bio raises funding to advance neuro pipeline

    BioWorld Science
    Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...
  • Other news to note for July 22, 2026

    BioWorld
    Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing